Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study

Novel therapeutic approach regulates all fibrotic pathologies driven by TGF-beta1, a major mediator of idiopathic pulmonary fibrosis

2011-02-14

(Press-News.org) MALVERN, PA – February 10, 2011 – Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P." The research showed that human Pentraxin-2 (PTX-2), also called human Serum amyloid P (SAP), potently inhibits all undesirable pro-fibrotic pathologies driven by TGFβ1 and represents a novel therapeutic approach for the treatment of diseases that involve lung fibrosis, including idiopathic pulmonary fibrosis (IPF). This research validates that PTX-2/SAP can have therapeutic effects even in conditions driven by TGFβ1 growth factor, and builds on the body of research showing the unique role of PTX-2/SAP in activating the body's natural ability to resolve tissue damage in disease processes that cause fibrosis and inflammation.

In this study, researchers examined the effects of PTX-2/SAP in the lung specific TGFβ1 transgenic mouse model, since many of the pathogenic mechanisms observed in lung fibrosis can be stimulated by the growth factor TGFβ1. Highlights of the results from this study validating the potential therapeutic effects of PTX-2/SAP in pulmonary fibrosis included:

PTX-2/SAP inhibited all of the pathologies driven by TGFβ1 including apoptosis, airway inflammation, pulmonary fibrocyte and M2 macrophage accumulation and collagen deposition, without affecting the levels of TGFβ1 in the lung;

An abbreviated therapeutic dose schedule was equally efficacious and demonstrated a sustained durability of effect following cessation of drug dosing, suggesting that intermittent dosing may be feasible in human patients;

PTX-2/SAP levels were reduced in the serum of IPF patients when compared to closely matched healthy control subjects and the levels of SAP in IPF patient serum directly correlated with lung function;

PTX-2/SAP directly inhibited M2 macrophage differentiation of monocytes obtained from IPF patients, suggesting that IPF patient monocytes would be responsive to PTX-2 therapy.

The findings regarding the effects of PTX-2/SAP in the lung specific TGFβ1 transgenic mouse model expand on previous preclinical studies, in which Promedior investigators determined that PTX-2/SAP potently inhibited lung fibrosis in both acute bleomycin-induced pulmonary fibrosis models and chronic asthma models through an inhibition of pulmonary fibrocyte and pro-fibrotic (M2) macrophage activation and accumulation, associated with increased macrophage production of the regulatory cytokine IL-10.

"Our research clearly shows the beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease," said lead author Erica L. Herzog, M.D., Ph.D., Assistant Professor of Medicine (Pulmonary), Yale School of Medicine. "These findings highlight the potential of Pentraxin-2 to be a potent and durable inhibitor at a pivotal point in the disease pathway of progressive pulmonary fibrotic diseases."

Based on this research and other clinical and preclinical studies, Promedior is developing a pipeline of drugs based upon recombinant forms of PTX-2/SAP for the treatment and prevention of fibrotic and inflammatory diseases. The company is conducting human clinical studies to evaluate Pentraxin-2 therapeutics for a number of fibrotic diseases, including IPF and post-surgical scarring in glaucoma patients.

"These new findings further support our confidence in Pentraxin-2 as a novel therapeutic for many severe and chronic inflammatory and fibrotic diseases, including IPF," said Mark L. Lupher, Jr., Ph.D., Chief Scientific Officer, Promedior. "By showing that PTX-2/SAP has dominant therapeutic effects even downstream of TGFβ1 pathways through the ability to inhibit pathologic fibrocytes and macrophages and promote regulatory macrophage function, these results further confirm that Pentraxin-2 regulates fundamental mechanisms of the innate immune system, opening an exciting new approach to treat inflammatory and fibrotic diseases."

### About IPF Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating and fatal disease that affects approximately 200,000 people in Europe and the United States combined, with approximately 30,000 new cases reported annually in each region.

IPF is characterized by inflammation and fibrosis in the lungs, hindering the ability to process oxygen and causing shortness of breath. IPF is a progressive disease, meaning that over time, lung scarring and related respiratory symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%. There are no medicines approved in the United States or Europe for the treatment of IPF.

About Pentraxin Therapeutics Promedior's proprietary platform of pentraxin therapeutics is based upon breakthrough discoveries in how the body's innate response to injury results in pathologic fibrosis and the loss of tissue and organ function. Promedior's novel therapeutics are designed to treat and prevent fibrotic pathology by regulating the common cellular mechanisms that control the initiation and progression of fibrosis across a variety of tissues and organ systems. Promedior's initial drug products are based upon the unique structure of Pentraxin-2, a naturally-occurring protein which has demonstrated a unique role in targeting monocytes at sites of tissue damage. Promedior's approach leverages the natural role of Pentraxin-2 in regulating the response of important immune and inflammatory processes in the body. Promedior has built a comprehensive patent estate for Pentraxin therapeutics, including recombinant human Pentraxin-2 (rhPTX2 or rhSAP), for a broad range of therapeutic applications in fibrosis and other inflammatory diseases.

About Promedior Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Utilizing this novel approach, Promedior is initially developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, and diabetic retinopathy (eye); pulmonary fibrosis, scleroderma and COPD (lung); and acute and chronic nephropathy (kidney). For additional information about Promedior, please visit http://www.promedior.com.

ELSE PRESS RELEASES FROM THIS DATE:

Chinks in the brain circuitry make some more vulnerable to anxiety

2011-02-14

Why do some people fret over the most trivial matters while others remain calm in the face of calamity? Researchers at the University of California, Berkeley, have identified two different chinks in our brain circuitry that explain why some of us are more prone to anxiety. Their findings, published today (Thursday, Feb. 10) in the journal Neuron may pave the way for more targeted treatment of chronic fear and anxiety disorders. Such conditions affect at least 25 million Americans and include panic attacks, social phobias, obsessive-compulsive behavior and post-traumatic ...

Tumor microvesicles reveal detailed genetic information

2011-02-14

The Massachusetts General Hospital (MGH) research team that first discovered tumor-associated RNA in tiny membrane-enclosed sacs released into the bloodstream by cancer cells has now found that these microvesicles also contain segments of tumor DNA, including retrotransposons – also called "jumping genes" – that copy and insert themselves into other areas of the genome. The investigators' report, which has been published in Nature Communications, is the first to show that microvesicles are involved in transferring retrotransposons between cells. "Retrotransposons' ...

UTHealth, Athersys preclinical research on stem cell therapy for stroke presented at AHA conference

2011-02-14

HOUSTON and LOS ANGELES – February 10th, 2011 – Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem®, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke. The study, conducted by leading researchers from the Department of Neurology at the UTHealth Medical School working in collaboration with scientists at Athersys, ...

Restructuring natural resource majors

2011-02-14

Madison, WI FEBRUARY 3, 2011 – A troublesome trend is occurring at colleges and universities around the country: fewer students are graduating with degrees in natural resource related degree programs. As a result, the number of qualified professionals to manage fish and wildlife programs is dwindling. What is even more troubling is that nationally, the percentage of students enrolling in the major has increased. For reasons unknown, students have been leaving the natural resource degree path after enrollment to pursue other degrees. Finding cause for the steady decline ...

Study related to diet soda and stroke risk is seriously flawed

2011-02-14

Contact: Stan Samples ssamples@kellencompany.com 404-252-3663 Calorie Control Council Study related to diet soda and stroke risk is seriously flawed Study is drawing a growing body of criticism and skepticism from experts in the field of nutrition and science The Calorie Control Council stated today that research findings presented during a poster session at the International Stroke Conference claiming an association between diet soft drink consumption and increased risk of stroke and heart attack are critically flawed. "The findings are so speculative and preliminary ...

Sandia security experts help Kazakhstan safely transport, store Soviet-era bomb materials

2011-02-14

ALBUQUERQUE, N.M. — A Sandia National Laboratories team helped reach a major milestone in the nation's nuclear nonproliferation efforts by working with the Central Asian country of Kazakhstan to move nuclear materials — enough to build an estimated 775 nuclear weapons — to safety. Sandia provided security and logistics expertise to complete the transfer across Kazakhstan of spent fuel containing 11 tons (10 metric tons) of highly enriched uranium and 3.3 tons (3 metric tons) of weapons-grade plutonium that had been stored in a BN-350 fast-breeder reactor in the busy Caspian ...

Wayne State study: Enhance romance by going out with other couples

2011-02-14

DETROIT— Romantic relationships often start out as enjoyable or even exciting, but sometimes may become routine and boring. A Wayne State University study reveals that dating couples that integrate other couples into their social lives are more likely to have happy and satisfying romantic relationships. Richard B. Slatcher, Ph.D., assistant professor of psychology in WSU's College of Liberal Arts and Sciences and a resident of Birmingham, Mich., specializes in social and health psychology. His recent research suggests that spending quality time with other couples may ...

VCU Massey first to combine targeted agents to kill multiple myeloma cells

2011-02-14

Richmond, Va. (Feb. 10, 2011) – Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo. Multiple myeloma is a cancer involving antibody-producing cells in the bone marrow, and, in most cases, is incurable. Targeted therapies work by interfering with ...

University of Arizona experts determine age of book 'nobody can read'

2011-02-14

University of Arizona researchers have cracked one of the puzzles surrounding what has been called "the world's most mysterious manuscript" – the Voynich manuscript, a book filled with drawings and writings nobody has been able to make sense of to this day. Using radiocarbon dating, a team led by Greg Hodgins in the UA's department of physics has found the manuscript's parchment pages date back to the early 15th century, making the book a century older than scholars had previously thought. This tome makes the "DaVinci Code" look downright lackluster: Rows of text ...

Powerful new ways to electronically mine research may lead to scientific breakthroughs

2011-02-14

The Internet has become not only a tool for disseminating knowledge through scientific publications, but it also has the potential to shape scientific research through expanding the field of metaknowledge—the study of knowledge itself. The new possibilities for metaknowledge include developing a better understanding of science's social context and the biases that can affect research findings and choices of research topics, according to an article published by University of Chicago researchers in the journal Science. Pooling research-related information online can shed ...

Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: